We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Aponvie will offer an option for the approximately 36 million patients undergoing surgical procedures in the country each year with high to moderate risk for PONV, Heron said. Read More
Bluebird Bio’s gene therapy Skysona (elivaldogene autotemcel) has snagged accelerated approval as a treatment for early, active cerebral adrenoleukodystrophy (CALD), an invariably fatal genetic disorder that strikes young boys. Read More